Overview

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc

Treatments:

Bevacizumab